Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor beta joining 1-3 (TRBJ1-3) is a **joining (J) gene segment** in the T cell receptor beta (TCRβ) locus, which participates in the **somatic recombination process** that generates the variable region of the TCRβ chain in T lymphocytes[1][3][5]. This recombination process, which also includes variable (V) and diversity (D) segments, creates the genetic diversity necessary for T cells to recognize a vast array of antigens presented by major histocompatibility complex (MHC) molecules[4][9]. The **TRBJ1-3 segment itself is not a receptor, protein, or druggable target**, but rather a genomic element involved in the assembly of TCRβ chains[1][3]. It does not have direct therapeutic targeting potential and thus is not a therapeutic target in the conventional sense[1]. Key points and clarifications: - **TRBJ1-3 is one of several J (joining) gene segments** used during **V(D)J recombination** in the thymus to generate the complementarity-determining region 3 (CDR3) of the TCRβ chain, which is critical for antigen specificity[3][4][5]. - **It is not a receptor, enzyme, transporter, or protein**, but a **genomic segment** classified within the immunoglobulin gene segments or recombination signal sequences category, often annotated as "Other" in target classification schemes. - While **essential for T cell function**, it is not independently linked to disease states except as part of the process generating TCR repertoire diversity[5]. There are no drugs known to act on this DNA segment, and it is not a therapeutic or diagnostic biomarker or candidate. - The correct entity for most drug targeting or functional antibody generation in immuno-oncology, for example, would be the **complete T cell receptor** or its protein products, not the discrete recombination segments like TRBJ1-3[1][9]. If you are looking for information about the **T cell receptor beta chain** as a functional protein complex or drug target, the entry should be for "T cell receptor beta chain" or "T cell receptor (TRB)," not the specific gene segment "TRBJ1-3"[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor beta joining 1-3 (TRBJ1-3).